OncoGenex Pharmaceuticals Company Description
OncoGenex Pharmaceuticals (formerly Sonus Pharmaceuticals) is on the hunt for new and better cancer therapies. With its 2008 merger with OncoGenex Technologies, the company took on a new name and an expanded pipeline of investigational oncology drugs. The merger contributed several candidates (including OGX-011, OGX-427, and OGX-225) that fight treatment-resistant tumors. Another candidate, SN2310, is a version of a proven class of oncology drugs called camptothecins. The company previously halted development on another investigational drug, a version of common cancer drug paclitaxel that used the firm's proprietary Tocosol drug delivery technology, following disappointing clinical trial results in 2007.
View the Comprehensive Company Description for OncoGenex Pharmaceuticals
The Company Description provides a historical perspective of OncoGenex Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of OncoGenex Pharmaceuticals's evolution in the marketplace.
